Next |
home / stock / clsn / clsn message board
Subject | By | Source | When |
---|---|---|---|
The typical gap and trap. | traderbbc1 | investorshub | 04/08/2022 1:18:09 PM |
lol.... | TheFinalCD | investorshub | 04/07/2022 5:17:10 PM |
How's this working out for you? | traderbbc1 | investorshub | 04/07/2022 3:51:43 PM |
https://finviz.com/quote.ashx?t=$CLSN looks like OS traded today | TheFinalCD | investorshub | 04/05/2022 6:42:58 PM |
https://twitter.com/READY 2 PROFIT/status/1511399414497218566 | TheFinalCD | investorshub | 04/05/2022 6:33:35 PM |
https://ih.advfn.com/stock-market/NASDAQ/celsion-$CLSN/stock-news/87762622/brookl | TheFinalCD | investorshub | 04/05/2022 6:15:37 PM |
Their effort was to avoid being delisted JMO | traderbbc1 | investorshub | 03/01/2022 2:57:01 PM |
OVER! | traderbbc1 | investorshub | 03/01/2022 2:54:54 PM |
it is over for this Trash!,, belongs to | Pennyes | investorshub | 02/08/2022 1:07:27 AM |
$CLSN voting request1?.. | Pennyes | investorshub | 02/02/2022 12:09:58 AM |
I agree. | traderbbc1 | investorshub | 09/02/2021 1:23:10 PM |
Strong buy low $3. soon..... | caloosa | investorshub | 09/02/2021 12:25:12 PM |
$CLSN buy 1.0900 | stocktrademan | investorshub | 08/08/2021 8:24:34 AM |
$CLSN...$1.54...in the P/M..Been adding the $1 range dip | georgie18 | investorshub | 06/14/2021 10:32:24 AM |
I believe it to be a negotiated price. | traderbbc1 | investorshub | 04/02/2021 2:55:13 PM |
how did they figure $1.30 per share, | skyzoom | investorshub | 03/31/2021 7:18:37 PM |
$CLSN...$1.39...added here...:party: | georgie18 | investorshub | 03/31/2021 1:32:18 PM |
Is it standard-operating-procedure of this company to proclaim | RNsidersbuying | investorshub | 03/19/2021 11:12:49 PM |
I like the entry. Big prospects here. Huge | traderbbc1 | investorshub | 03/15/2021 3:36:46 PM |
$CLSN...$2.22...Taking a starter here...Looking for a Double Top | georgie18 | investorshub | 03/15/2021 11:01:35 AM |
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...